Safety and effectiveness of primary systemic therapy with docetaxel and trastuzumab in HER-2 positive breast cancer.

被引：0
|
作者：
Griggs, JJ [1 ]
Schiffhauer, LM [1 ]
Sahasrabudhe, DM [1 ]
Pandya, KJ [1 ]
Caldwell, C [1 ]
Peacock, J [1 ]
Messina, P [1 ]
Spreng, E [1 ]
Bourne, P [1 ]
McGuire, GM [1 ]
机构：
[1] Univ Rochester, Rochester, NY 14627 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：76S / 76S
页数：1
相关论文
共 50 条
  • [31] Recent trends of HER-2 testing and trastuzumab therapy for breast cancer
    Kurosumi, Masafumi
    BREAST CANCER, 2009, 16 (04) : 284 - 287
  • [32] Complete response after docetaxel plus pertuzumab plus trastuzumab chemotherapy for multimetastatic positive Her-2 breast cancer
    Lai-Tiong, F.
    Van-Hulst, S.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (04) : 662 - 664
  • [33] Role of radiation induced β1-integrin expression in trastuzumab resistance in Her-2 positive breast cancer.
    Thoms, J.
    Sabri, S.
    Lesniak, D.
    Murray, D.
    Abdulkarim, B.
    CANCER RESEARCH, 2009, 69 (02) : 160S - 161S
  • [34] Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy
    Otchere, Prince
    Adekoya, Olusola
    Governor, Samuel B. B.
    Vuppuluri, Naveen
    Prabhakar, Akruti
    Pak, Stella
    Oppong-Nkrumah, Oduro
    Cook, Francis
    Bohinc, Rudy
    Aune, Gregory
    CARDIO-ONCOLOGY, 2023, 9 (01)
  • [35] Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
    Sagar Sardesai
    Jasmine Sukumar
    Mahmoud Kassem
    Marilly Palettas
    Julie Stephens
    Evan Morgan
    Daniel Addison
    Ragavendra Baliga
    Daniel G. Stover
    Jeffrey VanDeusen
    Nicole Williams
    Mathew Cherian
    Maryam Lustberg
    Robert Wesolowski
    Bhuvaneswari Ramaswamy
    Cardio-Oncology, 6
  • [36] Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
    Sardesai, Sagar
    Sukumar, Jasmine
    Kassem, Mahmoud
    Palettas, Marilly
    Stephens, Julie
    Morgan, Evan
    Addison, Daniel
    Baliga, Ragavendra
    Stover, Daniel G.
    VanDeusen, Jeffrey
    Williams, Nicole
    Cherian, Mathew
    Lustberg, Maryam
    Wesolowski, Robert
    Ramaswamy, Bhuvaneswari
    CARDIO-ONCOLOGY, 2020, 6 (01)
  • [37] Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy
    Prince Otchere
    Olusola Adekoya
    Samuel B. Governor
    Naveen Vuppuluri
    Akruti Prabhakar
    Stella Pak
    Oduro Oppong-Nkrumah
    Francis Cook
    Rudy Bohinc
    Gregory Aune
    Cardio-Oncology, 9
  • [38] Weekly docetaxel (Taxotere®) and trastuzumab (Herceptin®) as primary therapy in stage III, HER-2 overexpressing breast cancer -: a Brazilian multicenter study.
    Bines, J
    Murad, A
    Lago, S
    Ferrari, B
    Andrade, J
    Filho, EA
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S56 - S56
  • [39] Safety of trastuzumab deruxtecan and radiation therapy in HER2-positive breast cancer patients
    Visani, Luca
    Ratosa, Ivica
    Ribnikar, Domen
    Becherini, Carlotta
    Bertini, Niccolo
    Bonaparte, Ilaria
    Stefanovski, Dimitar
    Dobnikar, Nika
    Desideri, Isacco
    Olmetto, Emanuela
    Mangoni, Monica
    Di Cataldo, Vanessa
    Peruzzi, Anna
    Mattioli, Chiara
    Cela, Doruntina
    Valzano, Marianna
    Salvestrini, Viola
    Scoccimarro, Erika
    Livi, Lorenzo
    Meattini, Icro
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S691 - S692
  • [40] Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer
    Masafumi Kurosumi
    Breast Cancer, 2009, 16 : 283 - 283
12345